<DOC>
	<DOCNO>NCT00501488</DOCNO>
	<brief_summary>The aim present study investigate association adiponectin gene polymorphism response rosiglitazone monotherapy T2D patient . A total 255 T2D patient 120 health volunteer enrol study . 42 T2D patient -11377 ( C/G ) +45 ( T/G ) genotypes select administrate orally 4mg rosiglitazone daily 12 consecutive week .</brief_summary>
	<brief_title>Effect Adiponectin Genetic Polymorphism Rosiglitazone Response</brief_title>
	<detailed_description>The aim present study investigate association adiponectin allele +45 ( T/G ) -11377 ( C/G ) polymorphisms response rosiglitazone monotherapy T2D patient . A total 255 T2D patient ( 138 male , 117 female ) age 25 70 year ( mean 48.6 ± 10.7 year ) 120 healthy control ( 53 female , 67 male ) age 25 70 year ( mean 47.1 ± 11.0 year ) enrol participate study . Physical examination , medical history serum biochemical test perform identify healthy T2D subject . The diagnosis criterion T2D patient make accord World Health Organization 1997 fast plasma glucose ( FPG  7.0 mmol/L ) and/or postprandial plasma glucose test ( PPG  11.1 mmol/L ) . The inclusion criterion subject subject range body mass index ( BMI ) 18.5 30 kg/m2 administrate PPAR agonists last 3 month . Patients receive insulin treatment , pregnant lactate woman , serious disease acute myocardial infarction , cerebral vascular accident , trauma , kidney disease liver disease exclude study . Table 1 show characteristic profile T2D patient healthy control . There statistical difference age , height , weight , BMI value T2D patient healthy control . All subject recruit local resident Changsha city , Hunan Province , P. R. China . The study protocol approve Ethics Committee Xiangya School Medicine , Central South University write informed consent obtain start study . A total 42 T2D patient ( 23 male , 19 female ) randomly select treat 4mg rosiglitazone daily 12 consecutive week without change previous medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>The diagnosis criterion T2D patient make accord World Health Organization 1997 fast plasma glucose ( FPG  7.0 mmol/L ) and/or postprandial plasma glucose test ( PPG  11.1 mmol/L ) The inclusion criterion subject subject range body mass index ( BMI ) 18.5 30 kg/square meter administrate PPAR agonists last 3 month . Patients receive insulin treatment , pregnant lactate woman , serious disease acute myocardial infarction , cerebral vascular accident , trauma , kidney disease liver disease exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>therapy</keyword>
	<keyword>volunteer</keyword>
</DOC>